Sierra Oncology, Inc. (SRRA) Social Stream
Sierra Oncology Inc (SRRA) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Sierra Oncology Inc.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
Over the past 22 months, SRRA's average price target has gone up $12.53.
Over the past 49 weeks, SRRA's average upside potential has been 62.43%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
SRRA Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
SRRA's average broker recommendation rating improved by 0.5 over the prior 151 days.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for SRRA as an investment opportunity.
- In the context of all US stocks, Sierra Oncology Inc's number of analysts covering the stock is higher than 195.93% of them.
- In the context of Pharmaceutical Products stocks, Sierra Oncology Inc's upside potential (average analyst target price relative to current price) is higher than 76.71% of them.
- In the context of stocks in the small market cap category, Sierra Oncology Inc's average analyst price target is higher than 561.9% of them.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, Sierra Oncology Inc's variance in analysts' estimates is lower than -108.82% of them.
Make investment decisions regarding SRRA using the data that counts. Try POWR Ratings for free.